A Novel Thermo-Expandable Ureteral Metal Stent for the Minimally Invasive Management of Ureteral Strictures

Abstract

The ureteral Memokath stent is a promising, safe, and efficient treatment option for the minimally invasive management of both benign and malignant ureteral strictures.

Impact of Thermo-Expandable Memokath Ureteral Stent on Renal Function in the Management of Ureteroileal Anastomotic Stricture

“…An accurate measure of stricture length is therefore paramount to adequately treat strictures in the long-term and avoid migration. Papatsoris et al [9] assessed the safety and efficacy of 86 MK stents in 73 patients for the management of malignant and benign ureteral strictures. After a mean follow-up period of 17.1 months, 68 (79%) stents remained in situ with an average stent indwelling time of 11.2 months.…”

“…Various minimally invasive strategies have been introduced to treat ureteroileal strictures, such as conventional ureteric stents, mechanical dilatation, and cold endoureterotomy, each with different success rates. The disadvantages of conventional ureteral stents are infection, bleeding, irritative symptoms, encrustation, and stone formation, all leading to a reduced quality of life [9]. Repetitive high pressure dilation with angioplasty balloon and cold cut procedures have been reported to have long-term success rates of 16 and 51%, respectively [7,10].…”

Two Thermoformable Spiral Metallic Ureteral Stents in a Patient with Ileal Conduit and Distal Stenosis of the Ureters

“…In the literature, the follow-up periods of Memokath stents range from 11 to 17.1 months [9,10]. The median indwelling time was 18 months according to study of Papatsoris and Buchholz [10].…”

“…The median indwelling time was 18 months according to study of Papatsoris and Buchholz [10]. The total cost of the Memokath 051 insertion was lower than the cost of frequent double-J stent replacements [10]. …”

Biomaterials in Urology - Beyond Drug Eluting and Degradable - A Rational Approach to Ureteral Stent Design

“…Metal ureteral stents were introduced by Pauer in 1992 (Pauer and Lugmayr 1992) and have been utilized in the treatment of malignant ureteric obstruction (Kulkarni and Bellamy 2001;Liatsikos, Karnabatidis et al 2009;Masood, Papatsoris et al 2010;Papatsoris and Buchholz 2010;Sountoulides, Kaplan et al 2010), ureteral strictures (Daskalopoulos, Hatzidakis et al 2001;Papatsoris and Buchholz 2010), and ureteropelvic junction obstruction Masood, Papatsoris et al 2010;Benson, Taylor et al 2011). Current problems associated with metallic stents include biofilm formation, infection, migration, and tissue hyperplasia leading to luminal obstruction Wah, Irving et al 2007;Liatsikos, Karnabatidis et al 2009;Sountoulides, Kaplan et al 2010).…”